Testimonials

Retatrutide 5mg

Retatrutide 5mg

Retatrutide is the most-referenced next-generation triple agonist in metabolic research. A 5mg lyophilised research peptide with HPLC purity targeting, clear labelling and UK dispatch. For controlled laboratory use only.

  • 5mg vialLyophilised research peptide, clearly labelled with batch identity.
  • Triple agonistStudied for GIP, GLP-1 and glucagon receptor activity in one compound.
  • Lab-grade supplyHPLC purity targeting and UK dispatch for controlled research use.
1
Three receptors. One compound.

Three receptors. One compound.

Single-agonist compounds hit one receptor. Dual agonists hit two. Retatrutide is studied for activity at three: GIP, GLP-1 and glucagon. That triple engagement is why it sits at the centre of next-generation multi-agonist metabolic research.

  • GIP receptorStudied for its role in nutrient signalling and metabolic pathway models.
  • GLP-1 receptorThe incretin pathway behind the most-cited appetite research.
  • Glucagon receptorThe third arm: energy expenditure signalling in research models.
1
Appetite regulation

Appetite regulation

The GLP-1 and GIP arms of Retatrutide are studied for their role in appetite signalling. Research interest centres on how multi-agonist engagement affects hunger pathways and food intake in controlled models, compared with single-agonist compounds.

  • Hunger signallingGLP-1 and GIP pathways are the most-studied appetite signals in incretin research.
  • Multi-agonist modelResearch compares triple engagement against single-agonist compounds.
  • Controlled modelsFindings come from controlled laboratory study designs, not anecdotes.
1
Energy use

Energy use

The glucagon arm sets Retatrutide apart. Glucagon receptor activity is studied for its role in energy expenditure, which is why triple-agonist research looks beyond appetite alone. Intake down, output up: that is the model researchers are testing.

  • Energy expenditureGlucagon receptor signalling is studied for its effect on energy output.
  • Beyond appetiteTriple-agonist models look at both sides of the energy equation.
  • Next-generationRetatrutide builds on single and dual-agonist research with a third pathway.
1
What is Retatrutide?

Retatrutide is a research peptide studied as a triple (GIP/GLP-1/glucagon) receptor agonist, used in laboratory and preclinical literature examining multi-agonist metabolic pathway models.

Is Retatrutide available now?

Retatrutide is coming soon. Subscribe on this page and we will email you the moment it is in stock.

What strength will it be supplied at?

5mg lyophilised vial, HPLC purity target ≥99%.